Page last updated: 2024-09-02

fingolimod hydrochloride and cyclohexanol

fingolimod hydrochloride has been researched along with cyclohexanol in 1 studies

Compound Research Comparison

Studies
(fingolimod hydrochloride)
Trials
(fingolimod hydrochloride)
Recent Studies (post-2010)
(fingolimod hydrochloride)
Studies
(cyclohexanol)
Trials
(cyclohexanol)
Recent Studies (post-2010) (cyclohexanol)
2,7711572,0624,5486911,355

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cassidy, MP; He, H; Milstien, S; Paugh, SW; Selley, DE; Sim-Selley, LJ; Spiegel, S1

Other Studies

1 other study(ies) available for fingolimod hydrochloride and cyclohexanol

ArticleYear
Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
    Molecular pharmacology, 2006, Volume: 70, Issue:1

    Topics: Animals; Benzoxazines; Binding, Competitive; Cell Line; CHO Cells; Cricetinae; Cricetulus; Cyclohexanes; Cyclohexanols; Endocytosis; Enzyme Activation; Fingolimod Hydrochloride; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Immunosuppressive Agents; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Morpholines; Naphthalenes; Phenols; Piperidines; Propylene Glycols; Proto-Oncogene Proteins c-akt; Pyrazoles; Radioligand Assay; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Sphingosine

2006